DelveInsight's Lipodystrophy - Epidemiology Forecast 2032 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Lipodystrophy in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Lipodystrophy Epidemiology Forecast | Lipodystrophy Prevalent population

DelveInsight&rsquo;s &lsquo;Lipodystrophy&nbsp; Overview - Epidemiology Forecast&ndash;2034&rsquo; report delivers an in-depth understanding of the Lipodystrophy&nbsp; historical and forecasted epidemiology as well as the Lipodystrophy epidemiology trends in the United States, EU4 (Germany, France, Italy, Spain) and the UK, and Japan.
<h2>Geographies Covered</h2>
<ul>
<li>The United States</li>
<li>EU4 (Germany, France, Italy, Spain) and the UK</li>
<li>Japan</li>
</ul>
Study Period: 2021-2034
<h2>Lipodystrophy Understanding</h2>
Lipodystrophy Overview
Lipodystrophy is a medical condition characterized by complete or partial loss of adipose tissue. Not infrequently, lipodystrophy occurs in combination with the pathological accumulation of adipose tissue at distinct anatomical sites. Patients with lipodystrophy exhibit numerous metabolic complications, which indicate the importance of adipose tissue as an active endocrine organ. The total amount and the appropriate distribution of adipose tissue depots contribute to the metabolic state. Genetic and molecular research has improved our understanding of the mechanisms underlying lipodystrophy. Circulating hormones secreted by the adipose tissue, such as leptin and adiponectin, are greatly reduced in distinct subpopulations of patients with lipodystrophy. This finding rationalizes the use of these adipokines or agents that increase their circulating levels, such as peroxisome proliferator-activated receptor ? (PPAR?) agonists, for therapeutic purposes. Other novel therapeutic approaches, including growth hormone and growth hormone-releasing factors, are also being studied as potential additions to the therapeutic armamentarium. New insights gained from research and clinical trials could potentially revolutionize the management of this difficult-to-treat condition.
Continued in the report&hellip;
&nbsp;
Types of Lipodystrophy
Lipodystrophies are categorized according to both the etiology (congenital or acquired) and the pattern of adipose tissue loss, which can be either generalized (affecting the whole body) or partial (affecting specific body regions).
<ul>
<li>Generalized lipodystrophy</li>
<li>Congenital generalized lipodystrophy</li>
</ul>
&nbsp;
Congenital generalized lipodystrophy (CGL), or Berardinelli&not;&ndash;Seip syndrome, is a rare autosomal recessive disorder that is characterized by a near total lack of body adipose tissue. Approximately 250 cases of CGL have been described in the literature. This syndrome is ubiquitous in all geographic regions, with the highest frequency reported in Brazil.
&nbsp;
CGL occurs most frequently in instances of parental consanguinity and is diagnosed soon after birth. Despite voracious appetites and accelerated linear growth rates, children with cGl demonstrate markedly reduced subcutaneous adiposity. CGL is also associated with diabetes mellitus, hypertriglyceridemia, hepatic steatosis, cirrhosis, acromegaloid features, and acanthosis nigricans. Cardiomyopathy, mild mental retardation, advanced bone age, cervical spine instability, and muscular weakness have also been reported. Reproductive function is severely impaired in women but usually unaffected in men. Females are commonly present with clitoromegaly, hirsutism, amenorrhea or irregular menstrual cycles, and ovarian cysts. Finally, levels of leptin and adiponectin, hormones produced in adipose tissue, are low in both sexes.
&nbsp;
Acquired generalized lipodystrophy
Acquired generalized lipodystrophy, or Lawrence&ndash;Seip syndrome, shares many features with CGL, including severely reduced subcutaneous adiposity, insulin resistance or diabetes mellitus, acanthosis nigricans, hypertriglyceridemia, hepatic steatosis, hypoleptinemia, and hypoadiponectinemia. In addition to reduced subcutaneous adiposity, adipose tissue is reduced in the palms, soles, and intra-abdominal areas.
Continued in the report&hellip;..
<h2>Lipodystrophy Epidemiology</h2>
The epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Cases of Lipodystrophy, Subtype-specific Cases of Lipodystrophy, Gender-specific Cases of Lipodystrophy covering the United States, the EU4 (Germany, France, Italy, Spain), UK and Japan from 2021 to 2034.
&nbsp;
Key Findings
<ul>
<li>In 2021, the total incident cases of Lipodystrophy in the US were ~1,050 cases, which are anticipated to increase in 2034.</li>
<li>EU4 and the UK, in 2021, accounted for ~1,850 cases of Lipodystrophy, which are anticipated to increase by the year 2034.</li>
<li>Among the EU4 countries, the highest number of cases of Lipodystrophy were found in France, i.e., ~760 cases in the year 2021, which are estimated to increase by the year 2034.</li>
<li>In 2021, the gender-specific cases of Lipodystrophy in the US were ~210 and ~840, for males and females, respectively. These cases are expected to increase during the forecast period.</li>
</ul>
Continued in the report&hellip;
&nbsp;
Learn how the therapeutic market will evolve and grow in the coming years:&nbsp;<a href="https://www.delveinsight.com/report-store/lipodystrophy-market">Lipodystrophy Market</a> &nbsp;
<h2>Scope of the Report</h2>
<ul>
<li>The report covers a descriptive overview of Lipodystrophy, explaining its procedure, types and indications.</li>
<li>The report provides insight into 7MM historical and forecasted patient pool covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom and Japan.</li>
<li>The report assesses the Lipodystrophy risk and burden.</li>
<li>The report provides the segmentation of the epidemiology for 7MM by segmented by &lsquo;Total Cases of Lipodystrophy, Subtype-specific Cases of Lipodystrophy and Gender-specific Cases of Lipodystrophy&rsquo;.</li>
</ul>
<h2>Report Highlights</h2>
<ul>
<li>10-year forecast of Lipodystrophy</li>
<li>7MM Coverage</li>
<li>Total Cases of Lipodystrophy</li>
<li>Subtype-specific Cases of Lipodystrophy</li>
<li>Gender-specific Cases of Lipodystrophy</li>
</ul>
<h2>Key Questions Answered</h2>
<ul>
<li>What are the risk, burdens, and unmet needs of Lipodystrophy?</li>
<li>What is the historical Lipodystrophy patient pool in the United States, EU4 (Germany, France, Italy, Spain), UK and Japan?</li>
<li>What would be the forecasted patient pool of Lipodystrophy at the 7MM Coverage level?</li>
<li>What will be the growth opportunities across the 7MM coverage with respect to the patient population pertaining to Lipodystrophy?</li>
<li>Out of the countries mentioned above, which country would have the highest cases of Lipodystrophy during the forecast period (2025-2034)?</li>
<li>At what CAGR the population is expected to grow across the 7MM Coverage during the forecast period (2025-2034)?</li>
</ul>
<h2>Reasons to buy</h2>
The Lipodystrophy report will allow the user to -
<ul>
<li>Develop business strategies by understanding the trends, shaping and driving the 7MM Lipodystrophy epidemiology.</li>
<li>The Lipodystrophy epidemiology report and model were written and developed by Masters and PhD level epidemiologists.</li>
<li>The Lipodystrophy epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.</li>
</ul>

1. Key Insights
2. Report Introduction
3. Lipodystrophy Overview at a Glance
4. Executive Summary of Lipodystrophy
5. Key events
6. Disease Background and Overview
6.1. Introduction
6.2. Types of lipodystrophy
6.2.1. Generalized lipodystrophy
6.2.2. Partial lipodystrophy
6.2.3. Pathophysiology
6.3. Diagnosis
6.3.1. Identification and differential diagnosis of lipodystrophy
6.4. Diagnosis of Lipodystrophy: Multi-society Practice Guideline (2016)
6.5. Establishing the presence of lipodystrophy
7. Current treatment of lipodystrophy
7.1. Lifestyle modification
7.2. Non-leptin based treatment
7.3. Leptin treatment
7.4. Additional treatments for specific comorbidities
7.5. Cosmetic treatment, counseling, and pain management
7.6. Treatment of Lipodystrophy Syndromes: Multi-society Practice Guideline (2016)
8. Methodology
9. Epidemiology and Patient Population
9.1. Key Findings
9.2. Assumptions and Rationale
9.3. Epidemiology Scenario: 7MM
9.3.1. Total Cases of Lipodystrophy in the 7MM
9.4. The United States
9.4.1. Total cases of Lipodystrophy in the United States
9.4.2. Subtype-specific Cases of Lipodystrophy in the United States
9.4.3. Gender-specific Cases of Lipodystrophy in the United States
9.5. EU4 and the UK
9.5.1. Total Cases of Lipodystrophy in EU4 and the UK
9.5.2. Subtype-specific Cases of Lipodystrophy in EU4 and the UK
9.5.3. Gender-specific cases of Lipodystrophy in EU4 and the UK
9.6. Japan
9.6.1. Total cases of Lipodystrophy in Japan
9.6.2. Subtype-specific Cases of Lipodystrophy in Japan
9.6.3. Gender-specific cases of Lipodystrophy in Japan
10. Appendix
10.1. Report Methodology
10.2. Bibliography
11. DelveInsight Capabilities
12. Disclaimer
13. About DelveInsight

DelveInsight's "Lipodystrophy - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Lipodystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Lipodystrophy Epidemiology

Lipodystrophy - Epidemiology Forecast - 2034

Lipodystrophy Epidemiology report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Lipodystrophy in the 7MM